Targeting ligand-dependent wnt pathway dysregulation in gastrointestinal cancers through porcupine inhibition

Area of Science:

• Oncology
• Molecular Biology
• Gastroenterology

Background:

• Gastrointestinal cancers are a leading cause of cancer mortality worldwide.
• Dysregulation of the Wnt signaling pathway is a common driver in the development of these cancers.
• Understanding upstream aberrations in the Wnt pathway is critical for therapeutic development.

Purpose of the Study:

• To review the role of Wnt pathway dysregulation in common gastrointestinal cancers.
• To focus on the nature and frequency of upstream Wnt pathway aberrations.
• To evaluate the therapeutic potential of Porcupine inhibitors.

Main Methods:

• Review of pre-clinical efficacy data for Porcupine inhibitors (in vitro and in vivo).
• Analysis of potential toxicities associated with Porcupine inhibitors.
• Summary of early-phase clinical trial data for Porcupine inhibitors.

Main Results:

• Tumors with upstream Wnt pathway aberrations are dependent on Wnt ligand.
• Porcupine inhibitors demonstrate pre-clinical efficacy in relevant cancer models.
• Early clinical trials and toxicity profiles are being assessed.

Conclusions:

• Targeting Porcupine offers a promising therapeutic strategy for gastrointestinal cancers with Wnt pathway aberrations.
• Biomarker-defined approaches are essential for patient selection.
• Combination therapies may enhance treatment outcomes.